Option Care Health, Inc.

What they do

Option Care Health operates a national network of 196 locations across 43 states, providing home infusion therapy for anti-infectives, nutrition support, chronic inflammatory disorders, neurological disorders, immunoglobulin therapy, and other acute and chronic conditions. The company contracts with managed care organizations, third-party payers, hospitals, physicians, and other referral sources, and delivers services under the direction of the patient's physician. Its multidisciplinary team of over 5,000 clinicians includes pharmacists, pharmacy technicians, nurses, and dietitians, and the company operates as a single segment: infusion services.

Revenue drivers

• Managed care organizations (MCOs) and other non-governmental payers — For the year ended December 31, 2025, 88% of revenue came from MCOs and other non-governmental payers, including Medicare Advantage plans, Managed Medicaid plans, pharmacy benefit managers (PBMs), and self-pay patients.
• Referral sources (hospitals, physicians, health systems) — The company has referral source intangible assets of $270.4 million (net) as of June 30, 2026, reflecting the value of patient referral relationships that drive demand for infusion services.
• Pharmaceutical manufacturer collaborations — The company partners with pharmaceutical manufacturers to distribute their products and support new launches, earning revenue from drug distribution and associated service fees.

Recent performance

In Q2 2026, net revenue was $1,442 million, up 1.9% year-over-year. GAAP net income rose 6.7% to $53.9 million, with GAAP diluted EPS of $0.35 (up 12.9%). Adjusted EBITDA was $117.5 million (up 3.0%) and adjusted diluted EPS was $0.45 (up 9.8%). The company generated $184 million of cash from operations in the quarter and repurchased $150 million of shares. As of June 30, 2026, cash was $193.8 million and total assets were $3,378.8 million.

Strategy

Management highlights 2026 strategic initiatives aimed at positioning the company for sustainable long-term growth. The focus is on leveraging its clinical platform and national scale to expand market opportunities and improve operational execution. The company repurchased $150 million of shares in Q2 2026, reflecting a capital allocation strategy to return value to shareholders. It continues to partner with health systems for transitional care and with manufacturers for new product launches, and maintains a diversified payer mix.

Risks

• Payer concentration — 88% of revenue comes from MCOs and non-governmental payers; losing a key relationship could reduce patient access and revenue.
• Pharmaceutical dependence — Revenue depends on manufacturers developing and marketing drugs compatible with home infusion; supply shortages or direct-to-patient sales could harm results.
• Competitive bidding — Payers periodically require competitive bidding, and the company may not be retained.
• Reimbursement risk — Changes in reimbursement from government programs or commercial insurers could materially affect financial condition.

Outlook

For full year 2026, management expects net revenue of $5.675 billion to $5.775 billion, adjusted diluted EPS of $1.85 to $1.92, adjusted EBITDA of $480 million to $495 million, and operating cash flow of at least $320 million. For Q3 2026, they expect sequential net revenue growth in the low to mid single-digits and sequential Adjusted EBITDA growth in the mid single-digits.